Complications Associated With Transvenous Cardiac Implantable Devices

12/15/2025

Annals On Call Podcast

0:00

25:18

Dr. Centor discusses complications of cardiac implantable electronic devices with Dr. Peter Zimetbaum.

More episodes from "Annals On Call Podcast"

Complications Associated With Transvenous Cardiac Implantable Devices
vor 19 Stunden
25:18
Dr. Centor discusses complications of cardiac implantable electronic devices with Dr. Peter Zimetbaum.
Cost-Effectiveness of Weight Loss Drugs for Knee Osteoarthritis
12/1/2025
25:17
Dr. Centor discusses the use of weight loss drugs to treat patients with knee osteoarthritis with Dr. David Felson.
Don't miss an episode of “Annals On Call Podcast” and subscribe to it in the GetPodcast app.
Palliative Care: A Family Perspective
11/17/2025
19:37
Dr. Centor discusses a family perspective on palliative care with Ms. Monica Wright, the author of an On Being a Patient essay.
What You May Have Missed in 2024: Part 3
11/3/2025
15:33
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
What You May Have Missed in 2024 - Part 2
10/20/2025
13:52
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
High-Concentration Cannabinoids: Are They Safe?
10/6/2025
29:05
Dr. Centor discusses currently available evidence about high-concentration cannabis products and mental health outcomes with Drs. Paula Riggs and Jonathan Samet.
What You May Have Missed in 2024: Part 1
9/15/2025
20:13
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
Fibrillation - When Ablation is the Way to Go
9/1/2025
22:36
Dr. Centor discusses the role of ablation in the management of patients with atrial fibrillation with Dr. Peter Zimetbaum.
Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes
8/18/2025
29:55
Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.
Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control is Inadequate on Dulaglutide
8/4/2025
21:11
Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.

More Episodes

Get the whole world of podcasts with the free GetPodcast app.

Subscribe to your favorite podcasts, listen to episodes offline and get thrilling recommendations.

Complications Associated With Transvenous Cardiac Implantable Devices

Annals On Call Podcast

More episodes from "Annals On Call Podcast"

Complications Associated With Transvenous Cardiac Implantable Devices

Cost-Effectiveness of Weight Loss Drugs for Knee Osteoarthritis

Palliative Care: A Family Perspective

What You May Have Missed in 2024: Part 3

What You May Have Missed in 2024 - Part 2

High-Concentration Cannabinoids: Are They Safe?

What You May Have Missed in 2024: Part 1

Fibrillation - When Ablation is the Way to Go

Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes

Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control is Inadequate on Dulaglutide